COO
Jeremy Chadwick, Ph.D. is the Chief Operating Officer of Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in targeted protein degradation[[1]](https://www.globenewswire.com/news-release/2023/05/22/2673217/0/en/Kymera-Appoints-Jeremy-Chadwick-Ph-D-as-Chief-Operating-Officer.html). He brings extensive experience in global development operations, regulatory affairs, and program management across the life sciences industry[[1]](https://www.globenewswire.com/news-release/2023/05/22/2673217/0/en/Kymera-Appoints-Jeremy-Chadwick-Ph-D-as-Chief-Operating-Officer.html). Prior to joining Kymera in May 2023, Chadwick served as Senior Vice President and Head of Global Development Office at Takeda Pharmaceuticals, where he oversaw regulatory affairs, drug safety, clinical supply chain, and global development operations[[1]](https://www.globenewswire.com/news-release/2023/05/22/2673217/0/en/Kymera-Appoints-Jeremy-Chadwick-Ph-D-as-Chief-Operating-Officer.html)[[2]](https://www.kymeratx.com/about-us/leadership/jeremy-chadwick-phd/). His career also includes senior development roles at Shire Pharmaceuticals as Group Vice President and Head of Clinical Development Operations, as well as positions at The Medicines Company, Synta Pharmaceuticals, Vertex Pharmaceuticals, and Glaxo Group Research, where he managed program management, regulatory affairs, biostatistics, and data management[[1]](https://www.globenewswire.com/news-release/2023/05/22/2673217/0/en/Kymera-Appoints-Jeremy-Chadwick-Ph-D-as-Chief-Operating-Officer.html)[[2]](https://www.kymeratx.com/about-us/leadership/jeremy-chadwick-phd/).
Chadwick holds a Ph.D. and M.S. in Statistics from the University of London and a B.S. in Mathematics from De Montfort University in the United Kingdom[[1]](https://www.globenewswire.com/news-release/2023/05/22/2673217/0/en/Kymera-Appoints-Jeremy-Chadwick-Ph-D-as-Chief-Operating-Officer.html)[[2]](https://www.kymeratx.com/about-us/leadership/jeremy-chadwick-phd/). He has been instrumental in multiple successful global drug approvals across numerous therapeutic areas and previously served as chairman of the Board of Directors at Accumulus Synergy, an organization developing a data exchange platform to enhance how biopharmaceutical innovators and regulators bring medicines to patients[[1]](https://www.globenewswire.com/news-release/2023/05/22/2673217/0/en/Kymera-Appoints-Jeremy-Chadwick-Ph-D-as-Chief-Operating-Officer.html)[[2]](https://www.kymeratx.com/about-us/leadership/jeremy-chadwick-phd/). As of 2026, Chadwick owns approximately 61,202 shares of Kymera Therapeutics stock[[4]](https://www.gurufocus.com/insider/56865/jeremy-g-chadwick).
View full insider profile →
